Search

Your search keyword '"T cells -- Health aspects"' showing total 220 results
Start Over Descriptor "T cells -- Health aspects" Journal business wire
220 results on '"T cells -- Health aspects"'

1. Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Subjects
T cells -- Health aspects, Immunotherapy -- Health aspects, Business, Business, international
Abstract

THOUSAND OAKS, Calif. -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with [...]

Published
2024

2. Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers

Subjects
Sanofi S.A. -- Licensing agreements, T cells -- Health aspects, Biotechnology -- Health aspects, Cells -- Health aspects, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, Business, international
Abstract

- Bolsters clinical pipeline and adds near-term value creation opportunities - - Licenses proprietary masking platform with goal of minimizing off-tumor toxicity and offering expanded therapeutic index in patients - [...]

Published
2024

3. Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel[R]) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Subjects
United States. Food and Drug Administration, T cells -- Health aspects, Diseases -- California, Drugs -- Prescribing, Immunotherapy -- Health aspects, Cancer -- Care and treatment, Drug approval -- Health aspects, Epstein-Barr virus -- Health aspects, Business, Business, international
Abstract

Prescription Drug User Fee Act (PDUFA) Target Action Date of January 15, 2025 If Approved, Tab-cel Would Be First Approved Therapy in U.S. for EBV+ PTLD BLA Acceptance Triggers $20 [...]

Published
2024

4. Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Subjects
T cells -- Health aspects, Immunotherapy -- Health aspects, Business, Business, international
Abstract

THOUSAND OAKS, Calif. -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with [...]

Published
2024

5. Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum

Subjects
T cells -- Health aspects, Immunotherapy -- Health aspects, Business, Business, international
Abstract

THOUSAND OAKS, Calif. -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with [...]

Published
2024

6. Atara Biotherapeutics' Ebvallo[TM] (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases

Subjects
T cells -- Health aspects, Diseases -- California, Immunotherapy -- Health aspects, Cancer -- Care and treatment, Business, Business, international
Abstract

Ebvallo is the First and Only Approved Therapy in Europe for Adults and Children with EBV+ PTLD THOUSAND OAKS, Calif. -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell [...]

Published
2024

7. iCell Presents Positive New Follow-up Clinical Data Confirming BCMA CD19 cCAR Safely Delivers Long-term Medication Free Complete Remission from Systemic Lupus Erythematosus & Lupus Nephritis at EULAR 2024

Subjects
Medical research -- Health aspects, Medicine, Experimental -- Health aspects, T cells -- Health aspects, Lupus -- Health aspects, Systemic lupus erythematosus -- Health aspects, Immunotherapy -- Health aspects, B cells -- Health aspects, Kidney diseases -- Health aspects, Business, Business, international
Abstract

New data demonstrate 92% of patients now meet DORIS complete remission criteria (mean 20 months follow up) iCell's BCMA CD19 cCAR was well tolerated; humoral immunity recovered in all LN [...]

Published
2024

8. Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Subjects
T cells -- Health aspects, Immunotherapy -- Health aspects, Business, Business, international
Abstract

THOUSAND OAKS, Calif. -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with [...]

Published
2024

9. Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting

Subjects
T cells -- Health aspects, Lupus -- Health aspects, Multiple sclerosis -- Health aspects, Diseases -- California, Systemic lupus erythematosus -- Health aspects, Immunotherapy -- Health aspects, B cells -- Health aspects, Business, Business, international
Abstract

ATA3219 Demonstrates Complete CD19-Specific B-Cell Depletion Against Systemic Lupus Erythematosus and Multiple Sclerosis Patient Peripheral Blood Mononuclear Cells ATA3219 Induces Lower Levels of Pro-Inflammatory Cytokines While Maintaining Cytotoxic Potency Compared [...]

Published
2024

10. Atara Biotherapeutics Submits Tabelecleucel (Tab-cel[R]) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA

Subjects
United States. Food and Drug Administration, T cells -- Health aspects, Diseases -- California, Immunotherapy -- Health aspects, Cancer -- Care and treatment, Drug approval -- Health aspects, Epstein-Barr virus -- Health aspects, Business, Business, international
Abstract

First Allogeneic T-Cell Therapy BLA Submission to U.S. Food and Drug Administration If Approved, Tab-cel Would be First Approved Therapy in U.S. for EBV+ PTLD Acceptance of BLA Will Trigger [...]

Published
2024

11. Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Subjects
T cells -- Health aspects, Immunotherapy -- Health aspects, Business, Business, international
Abstract

THOUSAND OAKS, Calif. -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with [...]

Published
2024

12. RootPath Announces Publication Demonstrating How Its Novel Gene Synthesis Technology Empowers Cell Therapy in Solid Tumor Cancers

Subjects
T cells -- Health aspects, Genes -- Health aspects, Cancer -- Care and treatment -- Genetic aspects -- Health aspects, Business, Business, international
Abstract

WATERTOWN, Mass. -- RootPath, a synthetic biology company that elevates the throughput of gene function interrogation by orders of magnitude, today announced a new publication in Nature Biotechnology detailing research [...]

Published
2024

13. Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Subjects
T cells -- Health aspects, Immunotherapy -- Health aspects, Business, Business, international
Abstract

THOUSAND OAKS, Calif. -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with [...]

Published
2024

14. Kelonia Therapeutics to Present Preclinical Data Highlighting Therapeutic Potential of in vivo CAR-T Cell Therapy in Multiple Myeloma

Subjects
T cells -- Health aspects, Global Positioning System -- Equipment and supplies, Multiple myeloma -- Health aspects, Chemotherapy -- Health aspects, Cancer -- Chemotherapy, GPS receiver, Business, Business, international
Abstract

- Preclinical data supports potential for iGPS([R]) particles to provide off-the-shelf in vivo CAR-T Cell therapies without need for lymphodepleting chemotherapy - BOSTON -- Kelonia Therapeutics, a biotech company revolutionizing [...]

Published
2024

15. Dassault Systemes and CDR-Life Collaborate to Accelerate Scientific Innovation for Cancer Therapies

Subjects
Dassault Systemes S.A. -- Innovations, Euronext Paris S.A. -- Innovations, T cells -- Health aspects, Antineoplastic agents -- Innovations, Immunotherapy -- Health aspects, Cancer -- Care and treatment -- Health aspects, Antimitotic agents -- Innovations, Business, Business, international
Abstract

* Dassault Systemes, a science-based leader in virtual twin experiences and CDR-Life, a Swiss biotherapeutics company, partnered to study the stability of antibody-based biologics * Dassault Systemes' Contract Research team [...]

Published
2024

16. Therapeutic Solutions International Announces Landmark Finding Regarding Mechanism of Action of its JadiCell Stem Cell Product

Subjects
Lung diseases -- Health aspects, T cells -- Health aspects, Stem cells -- Health aspects, Business, Business, international
Abstract

Potent Activation of Naturally Occurring 'Healing Cells' That Amplify Therapeutic Effects of Stem Cells Discovered ELK CITY, Idaho -- Therapeutic Solutions International, Inc. (TSOI), announced today results of ongoing experiments [...]

Published
2024

17. Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy

Subjects
United States. Food and Drug Administration, T cells -- Health aspects, Nephritis -- Care and treatment, Lupus -- Care and treatment, Lymphomas -- Care and treatment, Immunotherapy -- Health aspects, B cells -- Health aspects, Cancer -- Care and treatment, Business, Business, international
Abstract

Second IND Clearance for ATA3219 Following Non-Hodgkin's Lymphoma (NHL) and First in an Autoimmune Disease Indication Initial Clinical Data in NHL Anticipated in H2 2024 and for Lupus Nephritis in [...]

Published
2024

18. Coya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer's Disease and Coya's Pathway to a 'Pipeline in a Product'

Subjects
United States. National Institutes of Health, T cells -- Health aspects, Intellectual property -- Health aspects, Alzheimer's disease -- Health aspects, Interleukins -- Product introduction, Stockholders -- Health aspects, Intellectual property, Business, Business, international
Abstract

* Combination biologics with LD IL-2 as a backbone may represent next-generation approaches that target complex immune pathways in neurodegenerative diseases * Expansion of COYA 302 into Alzheimer's Disease leverages [...]

Published
2024

19. Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis

Subjects
T cells -- Health aspects, Nephritis -- Drug therapy, Lupus -- Drug therapy, Lymphomas -- Drug therapy, Immunotherapy -- Health aspects, B cells -- Health aspects, Business, Business, international
Abstract

ATA3219 is an Allogeneic CAR T-Cell Therapy Targeting CD19+ B Cells to Potentially Address the Root Cause of Lupus Nephritis (LN) ATA3219 Is Designed to Combine the Natural Biology of [...]

Published
2024

20. Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel[R] Data in The Lancet Oncology

Subjects
T cells -- Health aspects, Immunotherapy -- Health aspects, Epstein-Barr virus -- Health aspects, Business, Business, international
Abstract

First Phase 3 Results Published for an Allogeneic T-Cell Therapy Significant 51.2% Objective Response Rate and 23.0 Month Median Duration of Response in Relapsed or Refractory EBV+ PTLD Patients U.S. [...]

Published
2024

21. Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference

Subjects
JPMorgan Chase & Co., T cells -- Health aspects, Lupus -- Health aspects, Immunotherapy -- Health aspects, Conferences and conventions -- Health aspects, Cancer -- Care and treatment, Epstein-Barr virus -- Health aspects, Business, Business, international
Abstract

Closing of Transaction with Pierre Fabre Laboratories to Expand Global Tab-cel([R]) Partnership Tab-cel BLA on Track for Submission in Q2 2024 Following Positive New Data from Pivotal ALLELE Study Expansion [...]

Published
2024

22. Atara Biotherapeutics Announces $15 Million Registered Direct Offering

Subjects
United States. Securities and Exchange Commission, T cells -- Health aspects, Immunotherapy -- Health aspects, Business, Business, international
Abstract

THOUSAND OAKS, Calif. -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with [...]

Published
2024

23. Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Subjects
JPMorgan Chase & Co., T cells -- Health aspects, Banking industry -- Health aspects, Immunotherapy -- Health aspects, Conferences and conventions -- Health aspects, Banking industry, Business, Business, international
Abstract

THOUSAND OAKS, Calif. -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with [...]

Published
2024

24. Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel[R] Partnership with Pierre Fabre Laboratories

Subjects
T cells -- Health aspects, International cooperation -- Health aspects, Immunotherapy -- Health aspects, Business, Business, international
Abstract

THOUSAND OAKS, Calif. -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with [...]

Published
2023

25. Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting

Subjects
T cells -- Health aspects, Immunotherapy -- Health aspects, Antigens -- Health aspects, Epstein-Barr virus -- Health aspects, Business, Business, international
Abstract

ATA3431 Preclinical Data Demonstrates Superior In Vivo Anti-tumor Activity, Survival, and Functional Persistence Compared to Autologous CAR-T Benchmark No Observed Treatment-Related Toxicities or Alloreactivity Data Supports Advancement Into IND-Enabling Studies [...]

Published
2023

26. Atara Biotherapeutics To Present Positive New Tab-cel[R] Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023

Subjects
Medical research -- Health aspects, Medicine, Experimental -- Health aspects, T cells -- Health aspects, Immunotherapy -- Health aspects, Epstein-Barr virus -- Health aspects, Business, Business, international
Abstract

Combined Analysis That Includes First Reported Data from Multicohort Phase 2 EBVision Trial Consistent with Previous Single-Center Experience Pooled Analysis Shows 77.8% Objective Response Rate (ORR) in 18 EBV+ CNS [...]

Published
2023

27. Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis

Subjects
T cells -- Health aspects, Multiple sclerosis -- Health aspects, Immunotherapy -- Health aspects, Clinical trials -- Health aspects, Business, Business, international
Abstract

P rimary Endpoint of Confirmed Disability Improvement at 12 Months Not Achieved Company to Further Analyze Data and Evaluate Strategic Options for ATA188 Program with Focusing of Resources and Planned [...]

Published
2023

28. Kite and Epic Bio Announce Collaboration to Develop New Therapies for Cancer

Subjects
Gilead Sciences Inc. -- Licensing agreements -- Research agreements, Biological products industry -- Research agreements -- Licensing agreements, T cells -- Health aspects, Cancer -- Health aspects, Company licensing agreement, Business, Business, international
Abstract

- Kite will gain access to Epic Bio's gene regulation platform to potentially develop next-generation cancer cell therapies - SANTA MONICA & SOUTH SAN FRANCISCO, Calif. -- Kite, a Gilead [...]

Published
2023

29. Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Subjects
T cells -- Health aspects, Immunotherapy -- Health aspects, Business, Business, international
Abstract

THOUSAND OAKS, Calif. -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with [...]

Published
2023

30. JURA Bio Announces Partnership With Replay Product Company Syena to Advance T Cell Receptor NK Therapies in Cancer

Subjects
T cells -- Health aspects, Biotechnology industry -- Research agreements -- Alliances and partnerships, Cancer -- Care and treatment -- Health aspects, Machine learning -- Health aspects, Business, Business, international
Abstract

* Collaboration leverages JURA Bio's T cell receptor (TCR) discovery platform to discover and develop innovative therapies by applying AI and machine learning * JURA Bio also announces $16.1M in [...]

Published
2023

31. Atara Biotherapeutics Announces Plans to Submit Tab-cel[R] BLA in Q2 2024 Following FDA Agreement on Comparability

Subjects
United States. Food and Drug Administration -- Planning, T cells -- Health aspects, Immunotherapy -- Health aspects, Cancer -- Care and treatment, Company business planning, Business, Business, international
Abstract

THOUSAND OAKS, Calif. -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with [...]

Published
2023

32. Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Subjects
T cells -- Health aspects, Immunotherapy -- Health aspects, Business, Business, international
Abstract

THOUSAND OAKS, Calif. -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with [...]

Published
2023

33. Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Subjects
T cells -- Health aspects, Immunotherapy -- Health aspects, Business, Business, international
Abstract

THOUSAND OAKS, Calif. -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with [...]

Published
2023

34. Eureka Therapeutics Awarded $10.6 Million CIRM Grant to Support Clinical Trial of ARTEMIS[R] T-Cell Therapy in Pediatric Liver Cancer

Subjects
California. Institute for Regenerative Medicine, T cells -- Health aspects, Cancer -- Care and treatment, Children -- Health aspects, Clinical trials -- Health aspects, Liver cancer -- Health aspects, Business, Business, international
Abstract

EMERYVILLE, Calif. -- Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat cancer, today announced that the California Institute for Regenerative Medicine (CIRM) awarded the Company [...]

Published
2023

35. Atara Biotherapeutics Presents Updated Tab-cel[R] Clinical Effectiveness Data at ASCO 2023

Subjects
T cells -- Health aspects, Immunotherapy -- Health aspects, Epstein-Barr virus -- Health aspects, Business, Business, international
Abstract

Real-World Results Demonstrate Objective Response Rate (ORR) of 67% in 24 EBV+ PTLD Patients 91% Overall Survival (OS) at One Year for Patients Responding to Tab-cel Compared to 34% for [...]

Published
2023

36. Transgene Presents Immunological Data Demonstrating that TG4001, a Novel Therapeutic Cancer Vaccine, Can Induce T-cell Responses Against HPV16 Antigens in the Ongoing Phase II Trial at ASCO 2023

Subjects
Euronext Paris S.A. -- Product development, T cells -- Health aspects, Immunotherapy -- Health aspects, Antigens -- Health aspects, Clinical trials -- Health aspects, Vaccines -- Product development, Securities industry -- Product development, Securities industry, Business, Business, international
Abstract

TG4001 can induce de novo immune responses against HPV16 antigens E6 and E7 in patients with advanced HPV16-positive anogenital cancers Patients with complete objective response showed strong vaccine-induced immunoreactivity Transgene [...]

Published
2023

37. Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Subjects
T cells -- Health aspects, Immunotherapy -- Health aspects, Business, Business, international
Abstract

THOUSAND OAKS, Calif. -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with [...]

Published
2023

38. Transgene to Present Data on its Two Therapeutic Cancer Vaccines at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Subjects
Euronext Paris S.A., Societies -- Health aspects, T cells -- Health aspects, Immunotherapy -- Health aspects, Vaccines -- Health aspects, Tumor antigens -- Health aspects, Securities industry -- Health aspects, Associations, institutions, etc. -- Health aspects, Securities industry, Business, Business, international
Abstract

Presentations include new data further demonstrating the immune responses induced by TG4001 and recently updated results from the adjuvant Phase I trial of neoantigen vaccine TG4050 in head and neck [...]

Published
2023

40. Seismic Therapeutic Announces Presentation of Preclinical Data Demonstrating Advances in Novel Biologics Discovery at the PEGS Boston Summit

Subjects
T cells -- Health aspects, Homeopathy -- Materia medica and therapeutics, Viral antibodies -- Health aspects, B cells -- Health aspects, Therapeutics -- Product development, Machine learning -- Health aspects, Enzymes -- Product development, Antibodies -- Health aspects, Business, Business, international
Abstract

Application of IMPACT platform to optimize antibody and enzyme therapeutics through parallelization and invisibilization to develop novel protein therapeutics CAMBRIDGE, Mass. -- Seismic Therapeutic, Inc., the machine learning immunology company, [...]

Published
2023

41. Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Subjects
T cells -- Health aspects, Immunotherapy -- Health aspects, Business, Business, international
Abstract

THOUSAND OAKS, Calif. -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with [...]

Published
2023

42. Orum Therapeutics Unveils New Program at AACR 2023, Highlighting Cbl-b Inhibitor-PD-1 Conjugate, and Presents New Data Supporting Clinical Development of Two GSPT1 Programs

Subjects
T cells -- Health aspects, Pertuzumab -- Health aspects, Business, Business, international, Mylotarg (Medication) -- Health aspects
Abstract

* Orum's new program in immuno-oncology achieves simultaneous blockade of PD-1/PD-L1 pathway and delivery of a Cbl-b inhibitor using anti-PD-1-Cbl-bi conjugates and demonstrates enhanced T cell activation in vitro compared [...]

Published
2023

43. Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Subjects
T cells -- Health aspects, Immunotherapy -- Health aspects, Business, Business, international
Abstract

THOUSAND OAKS, Calif. -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with [...]

Published
2023

44. Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Subjects
T cells -- Health aspects, Immunotherapy -- Health aspects, Business, Business, international
Abstract

THOUSAND OAKS, Calif. -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with [...]

Published
2023

45. Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Subjects
T cells -- Health aspects, Stock options -- Health aspects, Immunotherapy -- Health aspects, Compensation management -- Health aspects, Business, Business, international
Abstract

THOUSAND OAKS, Calif. -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with [...]

Published
2023

46. Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Subjects
T cells -- Health aspects, Stock options -- Health aspects, Immunotherapy -- Health aspects, Compensation management -- Health aspects, Business, Business, international
Abstract

THOUSAND OAKS, Calif. -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with [...]

Published
2023

47. Atara Biotherapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Subjects
JPMorgan Chase & Co., T cells -- Health aspects, Banking industry -- Health aspects, Immunotherapy -- Health aspects, Conferences and conventions -- Health aspects, Banking industry, Business, Business, international
Abstract

THOUSAND OAKS, Calif. -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with [...]

Published
2023

48. Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement with HealthCare Royalty

Subjects
T cells -- Health aspects, Cash transactions -- Health aspects, Immunotherapy -- Health aspects, Business, Business, international
Abstract

HealthCare Royalty Receives Specified Milestones and Royalties for Ebvallo(TM)in Europe in Exchange for Upfront Cash Payment to Atara Non-Dilutive Funding Further Extends Atara's Cash Runway Incremental to $40 Million of [...]

Published
2022

49. Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Subjects
T cells -- Health aspects, Stock options -- Health aspects, Immunotherapy -- Health aspects, Compensation management -- Health aspects, Business, Business, international
Abstract

THOUSAND OAKS, Calif. -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with [...]

Published
2022

50. Atara Biotherapeutics Presents Updated Clinical Data from Pivotal Phase 3 Trial (ALLELE) of Tab-cel[R] at the 64th American Society of Hematology (ASH) Annual Meeting

Subjects
T cells -- Health aspects, Trade and professional associations -- Health aspects, Immunotherapy -- Health aspects, Epstein-Barr virus -- Health aspects, Business, Business, international
Abstract

Phase 3 ALLELE Study Shows 51.2% Objective Response Rate (ORR) in 43 EBV+ PTLD Patients Median Duration of Response (DOR) of 23.0 Months Median Overall Survival of 18.4 Months with [...]

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results